Adverse events affecting ≥5% of patients in either group
Hyperkalemia, nasopharyngitis, arthralgia, back pain, urinary tract infection, diarrhea, anemia, hypertension, upper respiratory tract infection, peripheral edema, decreased GFR, hypoglycemia, dizziness, bronchitis, constipation, and pneumonia were adverse events affecting 5% of patients in either group. Patients treated with Finerenone had an increased risk of hyperkalemia, anemia, decreased eGFR, dizziness, upper respiratory tract infection, diarrhea, and arthralgia, but a decreased risk of hypoglycemia, pneumonia, peripheral edema, constipation, UTI, bronchitis, nasopharyngitis, and hypertension. Table 3 details the adverse events that affected five percent of the population.